ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Oncolytic Virus Manufacturing Services Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-33A17307
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Oncolytic Virus Manufacturing Services Market Research Report 2024
BUY CHAPTERS

Global Oncolytic Virus Manufacturing Services Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-33A17307
Report
October 2025
Pages:138
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Recipharm (Vibalogics)
Idt Biologika
FUJIFILM Diosynth Biotechnologies
Exothera
Lonza
Creative-Biolabs
Takara Bio
Libentech
ABL, Inc.
Nabios
HALIX
OBiO Technology
Porton Advanced
WuXi ATU
Genevoyager

Oncolytic Virus Manufacturing Services Market

The global Oncolytic Virus Manufacturing Services market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Oncolytic virus manufacturing services refer to specialized biomanufacturing processes that involve the production of oncolytic viruses, which are viruses engineered or naturally occurring that selectively infect and kill cancer cells. These services encompass a range of activities, from virus design and development to large-scale production and quality control, ensuring that the oncolytic viruses are safe, effective, and meet regulatory standards for clinical and commercial use.
From a downstream perspective, R&D accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Oncolytic Virus Manufacturing Services leading manufacturers including Recipharm (Vibalogics), IDT Biologika, FUJIFILM Diosynth Biotechnologies, Exothera, Lonza, Creative Biolabs, Takara Bio, Libentech, ABL, Nabios, etc., dominate supply; the top five capture approximately % of global revenue, with Recipharm (Vibalogics) leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Oncolytic Virus Manufacturing Services market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Oncolytic Virus Manufacturing Services Market Report

Report Metric Details
Report Name Oncolytic Virus Manufacturing Services Market
Segment by Type
Segment by Application
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Recipharm (Vibalogics), IDT Biologika, FUJIFILM Diosynth Biotechnologies, Exothera, Lonza, Creative Biolabs, Takara Bio, Libentech, ABL, Nabios, Halix, Obio Technology, Porton Advanced, WuXi ATU, Genevoyager
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Oncolytic Virus Manufacturing Services study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Oncolytic Virus Manufacturing Services Market report?

Ans: The main players in the Oncolytic Virus Manufacturing Services Market are Recipharm (Vibalogics), IDT Biologika, FUJIFILM Diosynth Biotechnologies, Exothera, Lonza, Creative Biolabs, Takara Bio, Libentech, ABL, Nabios, Halix, Obio Technology, Porton Advanced, WuXi ATU, Genevoyager

What are the Application segmentation covered in the Oncolytic Virus Manufacturing Services Market report?

Ans: The Applications covered in the Oncolytic Virus Manufacturing Services Market report are R&D, Biopharmaceutical Manufacturers, Others

What are the Type segmentation covered in the Oncolytic Virus Manufacturing Services Market report?

Ans: The Types covered in the Oncolytic Virus Manufacturing Services Market report are Oncolytic Herpes Simplex Virus, Oncolytic Adenovirus, Oncolytic Vaccinia Virus, Others

Recommended Reports

Cancer Therapy Markets

Cell & Gene Therapy

Biopharma Manufacturing

1 Study Coverage
1.1 Introduction to Oncolytic Virus Manufacturing Services: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Oncolytic Virus Manufacturing Services Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Oncolytic Herpes Simplex Virus
1.2.3 Oncolytic Adenovirus
1.2.4 Oncolytic Vaccinia Virus
1.2.5 Others
1.3 Market Segmentation by Application
1.3.1 Global Oncolytic Virus Manufacturing Services Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 R&D
1.3.3 Biopharmaceutical Manufacturers
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Oncolytic Virus Manufacturing Services Revenue Estimates and Forecasts 2020-2031
2.2 Global Oncolytic Virus Manufacturing Services Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Oncolytic Virus Manufacturing Services Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Oncolytic Virus Manufacturing Services Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Oncolytic Herpes Simplex Virus Market Size by Players
3.3.2 Oncolytic Adenovirus Market Size by Players
3.3.3 Oncolytic Vaccinia Virus Market Size by Players
3.3.4 Others Market Size by Players
3.4 Global Oncolytic Virus Manufacturing Services Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Oncolytic Virus Manufacturing Services Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Oncolytic Virus Manufacturing Services Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Oncolytic Virus Manufacturing Services Market Size by Type (2020-2031)
6.4 North America Oncolytic Virus Manufacturing Services Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Oncolytic Virus Manufacturing Services Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Oncolytic Virus Manufacturing Services Market Size by Type (2020-2031)
7.4 Europe Oncolytic Virus Manufacturing Services Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Oncolytic Virus Manufacturing Services Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Oncolytic Virus Manufacturing Services Market Size by Type (2020-2031)
8.4 Asia-Pacific Oncolytic Virus Manufacturing Services Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Oncolytic Virus Manufacturing Services Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Oncolytic Virus Manufacturing Services Market Size by Type (2020-2031)
9.4 Central and South America Oncolytic Virus Manufacturing Services Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Oncolytic Virus Manufacturing Services Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Oncolytic Virus Manufacturing Services Market Size by Type (2020-2031)
10.4 Middle East and Africa Oncolytic Virus Manufacturing Services Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Oncolytic Virus Manufacturing Services Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Recipharm (Vibalogics)
11.1.1 Recipharm (Vibalogics) Corporation Information
11.1.2 Recipharm (Vibalogics) Business Overview
11.1.3 Recipharm (Vibalogics) Oncolytic Virus Manufacturing Services Product Features and Attributes
11.1.4 Recipharm (Vibalogics) Oncolytic Virus Manufacturing Services Revenue and Gross Margin (2020-2025)
11.1.5 Recipharm (Vibalogics) Oncolytic Virus Manufacturing Services Revenue by Product in 2024
11.1.6 Recipharm (Vibalogics) Oncolytic Virus Manufacturing Services Revenue by Application in 2024
11.1.7 Recipharm (Vibalogics) Oncolytic Virus Manufacturing Services Revenue by Geographic Area in 2024
11.1.8 Recipharm (Vibalogics) Oncolytic Virus Manufacturing Services SWOT Analysis
11.1.9 Recipharm (Vibalogics) Recent Developments
11.2 IDT Biologika
11.2.1 IDT Biologika Corporation Information
11.2.2 IDT Biologika Business Overview
11.2.3 IDT Biologika Oncolytic Virus Manufacturing Services Product Features and Attributes
11.2.4 IDT Biologika Oncolytic Virus Manufacturing Services Revenue and Gross Margin (2020-2025)
11.2.5 IDT Biologika Oncolytic Virus Manufacturing Services Revenue by Product in 2024
11.2.6 IDT Biologika Oncolytic Virus Manufacturing Services Revenue by Application in 2024
11.2.7 IDT Biologika Oncolytic Virus Manufacturing Services Revenue by Geographic Area in 2024
11.2.8 IDT Biologika Oncolytic Virus Manufacturing Services SWOT Analysis
11.2.9 IDT Biologika Recent Developments
11.3 FUJIFILM Diosynth Biotechnologies
11.3.1 FUJIFILM Diosynth Biotechnologies Corporation Information
11.3.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.3.3 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing Services Product Features and Attributes
11.3.4 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing Services Revenue and Gross Margin (2020-2025)
11.3.5 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing Services Revenue by Product in 2024
11.3.6 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing Services Revenue by Application in 2024
11.3.7 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing Services Revenue by Geographic Area in 2024
11.3.8 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing Services SWOT Analysis
11.3.9 FUJIFILM Diosynth Biotechnologies Recent Developments
11.4 Exothera
11.4.1 Exothera Corporation Information
11.4.2 Exothera Business Overview
11.4.3 Exothera Oncolytic Virus Manufacturing Services Product Features and Attributes
11.4.4 Exothera Oncolytic Virus Manufacturing Services Revenue and Gross Margin (2020-2025)
11.4.5 Exothera Oncolytic Virus Manufacturing Services Revenue by Product in 2024
11.4.6 Exothera Oncolytic Virus Manufacturing Services Revenue by Application in 2024
11.4.7 Exothera Oncolytic Virus Manufacturing Services Revenue by Geographic Area in 2024
11.4.8 Exothera Oncolytic Virus Manufacturing Services SWOT Analysis
11.4.9 Exothera Recent Developments
11.5 Lonza
11.5.1 Lonza Corporation Information
11.5.2 Lonza Business Overview
11.5.3 Lonza Oncolytic Virus Manufacturing Services Product Features and Attributes
11.5.4 Lonza Oncolytic Virus Manufacturing Services Revenue and Gross Margin (2020-2025)
11.5.5 Lonza Oncolytic Virus Manufacturing Services Revenue by Product in 2024
11.5.6 Lonza Oncolytic Virus Manufacturing Services Revenue by Application in 2024
11.5.7 Lonza Oncolytic Virus Manufacturing Services Revenue by Geographic Area in 2024
11.5.8 Lonza Oncolytic Virus Manufacturing Services SWOT Analysis
11.5.9 Lonza Recent Developments
11.6 Creative Biolabs
11.6.1 Creative Biolabs Corporation Information
11.6.2 Creative Biolabs Business Overview
11.6.3 Creative Biolabs Oncolytic Virus Manufacturing Services Product Features and Attributes
11.6.4 Creative Biolabs Oncolytic Virus Manufacturing Services Revenue and Gross Margin (2020-2025)
11.6.5 Creative Biolabs Recent Developments
11.7 Takara Bio
11.7.1 Takara Bio Corporation Information
11.7.2 Takara Bio Business Overview
11.7.3 Takara Bio Oncolytic Virus Manufacturing Services Product Features and Attributes
11.7.4 Takara Bio Oncolytic Virus Manufacturing Services Revenue and Gross Margin (2020-2025)
11.7.5 Takara Bio Recent Developments
11.8 Libentech
11.8.1 Libentech Corporation Information
11.8.2 Libentech Business Overview
11.8.3 Libentech Oncolytic Virus Manufacturing Services Product Features and Attributes
11.8.4 Libentech Oncolytic Virus Manufacturing Services Revenue and Gross Margin (2020-2025)
11.8.5 Libentech Recent Developments
11.9 ABL
11.9.1 ABL Corporation Information
11.9.2 ABL Business Overview
11.9.3 ABL Oncolytic Virus Manufacturing Services Product Features and Attributes
11.9.4 ABL Oncolytic Virus Manufacturing Services Revenue and Gross Margin (2020-2025)
11.9.5 ABL Recent Developments
11.10 Nabios
11.10.1 Nabios Corporation Information
11.10.2 Nabios Business Overview
11.10.3 Nabios Oncolytic Virus Manufacturing Services Product Features and Attributes
11.10.4 Nabios Oncolytic Virus Manufacturing Services Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Halix
11.11.1 Halix Corporation Information
11.11.2 Halix Business Overview
11.11.3 Halix Oncolytic Virus Manufacturing Services Product Features and Attributes
11.11.4 Halix Oncolytic Virus Manufacturing Services Revenue and Gross Margin (2020-2025)
11.11.5 Halix Recent Developments
11.12 Obio Technology
11.12.1 Obio Technology Corporation Information
11.12.2 Obio Technology Business Overview
11.12.3 Obio Technology Oncolytic Virus Manufacturing Services Product Features and Attributes
11.12.4 Obio Technology Oncolytic Virus Manufacturing Services Revenue and Gross Margin (2020-2025)
11.12.5 Obio Technology Recent Developments
11.13 Porton Advanced
11.13.1 Porton Advanced Corporation Information
11.13.2 Porton Advanced Business Overview
11.13.3 Porton Advanced Oncolytic Virus Manufacturing Services Product Features and Attributes
11.13.4 Porton Advanced Oncolytic Virus Manufacturing Services Revenue and Gross Margin (2020-2025)
11.13.5 Porton Advanced Recent Developments
11.14 WuXi ATU
11.14.1 WuXi ATU Corporation Information
11.14.2 WuXi ATU Business Overview
11.14.3 WuXi ATU Oncolytic Virus Manufacturing Services Product Features and Attributes
11.14.4 WuXi ATU Oncolytic Virus Manufacturing Services Revenue and Gross Margin (2020-2025)
11.14.5 WuXi ATU Recent Developments
11.15 Genevoyager
11.15.1 Genevoyager Corporation Information
11.15.2 Genevoyager Business Overview
11.15.3 Genevoyager Oncolytic Virus Manufacturing Services Product Features and Attributes
11.15.4 Genevoyager Oncolytic Virus Manufacturing Services Revenue and Gross Margin (2020-2025)
11.15.5 Genevoyager Recent Developments
12 Oncolytic Virus Manufacturing ServicesIndustry Chain Analysis
12.1 Oncolytic Virus Manufacturing Services Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Oncolytic Virus Manufacturing Services Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Oncolytic Virus Manufacturing Services Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Recipharm (Vibalogics)
Idt Biologika
FUJIFILM Diosynth Biotechnologies
Exothera
Lonza
Creative-Biolabs
Takara Bio
Libentech
ABL, Inc.
Nabios
HALIX
OBiO Technology
Porton Advanced
WuXi ATU
Genevoyager
List of Tables
 Table 1. Global Oncolytic Virus Manufacturing Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Oncolytic Virus Manufacturing Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Oncolytic Virus Manufacturing Services Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Oncolytic Virus Manufacturing Services Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Oncolytic Virus Manufacturing Services Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Oncolytic Virus Manufacturing Services Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Oncolytic Virus Manufacturing Services Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Oncolytic Virus Manufacturing Services by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Manufacturing Services as of 2024)
 Table 11. Global Oncolytic Virus Manufacturing Services Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Oncolytic Virus Manufacturing Services Companies Headquarters
 Table 13. Global Oncolytic Virus Manufacturing Services Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Oncolytic Virus Manufacturing Services Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Oncolytic Virus Manufacturing Services Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Oncolytic Virus Manufacturing Services Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Oncolytic Virus Manufacturing Services Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Oncolytic Virus Manufacturing Services High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Oncolytic Virus Manufacturing Services Growth Accelerators and Market Barriers
 Table 25. North America Oncolytic Virus Manufacturing Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Oncolytic Virus Manufacturing Services Growth Accelerators and Market Barriers
 Table 27. Europe Oncolytic Virus Manufacturing Services Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Oncolytic Virus Manufacturing Services Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Oncolytic Virus Manufacturing Services Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Oncolytic Virus Manufacturing Services Investment Opportunities and Key Challenges
 Table 31. Central and South America Oncolytic Virus Manufacturing Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Oncolytic Virus Manufacturing Services Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Oncolytic Virus Manufacturing Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Recipharm (Vibalogics) Corporation Information
 Table 35. Recipharm (Vibalogics) Description and Major Businesses
 Table 36. Recipharm (Vibalogics) Product Features and Attributes
 Table 37. Recipharm (Vibalogics) Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Recipharm (Vibalogics) Revenue Proportion by Product in 2024
 Table 39. Recipharm (Vibalogics) Revenue Proportion by Application in 2024
 Table 40. Recipharm (Vibalogics) Revenue Proportion by Geographic Area in 2024
 Table 41. Recipharm (Vibalogics) Oncolytic Virus Manufacturing Services SWOT Analysis
 Table 42. Recipharm (Vibalogics) Recent Developments
 Table 43. IDT Biologika Corporation Information
 Table 44. IDT Biologika Description and Major Businesses
 Table 45. IDT Biologika Product Features and Attributes
 Table 46. IDT Biologika Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. IDT Biologika Revenue Proportion by Product in 2024
 Table 48. IDT Biologika Revenue Proportion by Application in 2024
 Table 49. IDT Biologika Revenue Proportion by Geographic Area in 2024
 Table 50. IDT Biologika Oncolytic Virus Manufacturing Services SWOT Analysis
 Table 51. IDT Biologika Recent Developments
 Table 52. FUJIFILM Diosynth Biotechnologies Corporation Information
 Table 53. FUJIFILM Diosynth Biotechnologies Description and Major Businesses
 Table 54. FUJIFILM Diosynth Biotechnologies Product Features and Attributes
 Table 55. FUJIFILM Diosynth Biotechnologies Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. FUJIFILM Diosynth Biotechnologies Revenue Proportion by Product in 2024
 Table 57. FUJIFILM Diosynth Biotechnologies Revenue Proportion by Application in 2024
 Table 58. FUJIFILM Diosynth Biotechnologies Revenue Proportion by Geographic Area in 2024
 Table 59. FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing Services SWOT Analysis
 Table 60. FUJIFILM Diosynth Biotechnologies Recent Developments
 Table 61. Exothera Corporation Information
 Table 62. Exothera Description and Major Businesses
 Table 63. Exothera Product Features and Attributes
 Table 64. Exothera Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Exothera Revenue Proportion by Product in 2024
 Table 66. Exothera Revenue Proportion by Application in 2024
 Table 67. Exothera Revenue Proportion by Geographic Area in 2024
 Table 68. Exothera Oncolytic Virus Manufacturing Services SWOT Analysis
 Table 69. Exothera Recent Developments
 Table 70. Lonza Corporation Information
 Table 71. Lonza Description and Major Businesses
 Table 72. Lonza Product Features and Attributes
 Table 73. Lonza Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Lonza Revenue Proportion by Product in 2024
 Table 75. Lonza Revenue Proportion by Application in 2024
 Table 76. Lonza Revenue Proportion by Geographic Area in 2024
 Table 77. Lonza Oncolytic Virus Manufacturing Services SWOT Analysis
 Table 78. Lonza Recent Developments
 Table 79. Creative Biolabs Corporation Information
 Table 80. Creative Biolabs Description and Major Businesses
 Table 81. Creative Biolabs Product Features and Attributes
 Table 82. Creative Biolabs Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Creative Biolabs Recent Developments
 Table 84. Takara Bio Corporation Information
 Table 85. Takara Bio Description and Major Businesses
 Table 86. Takara Bio Product Features and Attributes
 Table 87. Takara Bio Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Takara Bio Recent Developments
 Table 89. Libentech Corporation Information
 Table 90. Libentech Description and Major Businesses
 Table 91. Libentech Product Features and Attributes
 Table 92. Libentech Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. Libentech Recent Developments
 Table 94. ABL Corporation Information
 Table 95. ABL Description and Major Businesses
 Table 96. ABL Product Features and Attributes
 Table 97. ABL Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. ABL Recent Developments
 Table 99. Nabios Corporation Information
 Table 100. Nabios Description and Major Businesses
 Table 101. Nabios Product Features and Attributes
 Table 102. Nabios Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. Nabios Recent Developments
 Table 104. Halix Corporation Information
 Table 105. Halix Description and Major Businesses
 Table 106. Halix Product Features and Attributes
 Table 107. Halix Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 108. Halix Recent Developments
 Table 109. Obio Technology Corporation Information
 Table 110. Obio Technology Description and Major Businesses
 Table 111. Obio Technology Product Features and Attributes
 Table 112. Obio Technology Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 113. Obio Technology Recent Developments
 Table 114. Porton Advanced Corporation Information
 Table 115. Porton Advanced Description and Major Businesses
 Table 116. Porton Advanced Product Features and Attributes
 Table 117. Porton Advanced Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 118. Porton Advanced Recent Developments
 Table 119. WuXi ATU Corporation Information
 Table 120. WuXi ATU Description and Major Businesses
 Table 121. WuXi ATU Product Features and Attributes
 Table 122. WuXi ATU Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 123. WuXi ATU Recent Developments
 Table 124. Genevoyager Corporation Information
 Table 125. Genevoyager Description and Major Businesses
 Table 126. Genevoyager Product Features and Attributes
 Table 127. Genevoyager Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 128. Genevoyager Recent Developments
 Table 129. Raw Materials Key Suppliers
 Table 130. Distributors List
 Table 131. Market Trends and Market Evolution
 Table 132. Market Drivers and Opportunities
 Table 133. Market Challenges, Risks, and Restraints
 Table 134. Research Programs/Design for This Report
 Table 135. Key Data Information from Secondary Sources
 Table 136. Key Data Information from Primary Sources


List of Figures
 Figure 1. Oncolytic Virus Manufacturing Services Product Picture
 Figure 2. Global Oncolytic Virus Manufacturing Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Oncolytic Herpes Simplex Virus Product Picture
 Figure 4. Oncolytic Adenovirus Product Picture
 Figure 5. Oncolytic Vaccinia Virus Product Picture
 Figure 6. Others Product Picture
 Figure 7. Global Oncolytic Virus Manufacturing Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 8. R&D
 Figure 9. Biopharmaceutical Manufacturers
 Figure 10. Others
 Figure 11. Oncolytic Virus Manufacturing Services Report Years Considered
 Figure 12. Global Oncolytic Virus Manufacturing Services Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 14. Global Oncolytic Virus Manufacturing Services Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 15. Global Oncolytic Virus Manufacturing Services Revenue Market Share by Region (2020-2031)
 Figure 16. Global Oncolytic Virus Manufacturing Services Revenue Market Share Ranking (2024)
 Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 18. Oncolytic Herpes Simplex Virus Revenue Market Share by Player in 2024
 Figure 19. Oncolytic Adenovirus Revenue Market Share by Player in 2024
 Figure 20. Oncolytic Vaccinia Virus Revenue Market Share by Player in 2024
 Figure 21. Others Revenue Market Share by Player in 2024
 Figure 22. Global Oncolytic Virus Manufacturing Services Revenue Market Share by Type (2020-2031)
 Figure 23. Global Oncolytic Virus Manufacturing Services Revenue Market Share by Application (2020-2031)
 Figure 24. North America Oncolytic Virus Manufacturing Services Revenue YoY (2020-2031) & (US$ Million)
 Figure 25. North America Top 5 Players Oncolytic Virus Manufacturing Services Revenue (US$ Million) in 2024
 Figure 26. North America Oncolytic Virus Manufacturing Services Revenue (US$ Million) by Type (2020 - 2031)
 Figure 27. North America Oncolytic Virus Manufacturing Services Revenue (US$ Million) by Application (2020-2031)
 Figure 28. US Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 29. Canada Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 30. Mexico Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 31. Europe Oncolytic Virus Manufacturing Services Revenue YoY (2020-2031) & (US$ Million)
 Figure 32. Europe Top 5 Players Oncolytic Virus Manufacturing Services Revenue (US$ Million) in 2024
 Figure 33. Europe Oncolytic Virus Manufacturing Services Revenue (US$ Million) by Type (2020-2031)
 Figure 34. Europe Oncolytic Virus Manufacturing Services Revenue (US$ Million) by Application (2020-2031)
 Figure 35. Germany Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 36. France Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 37. U.K. Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 38. Italy Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 39. Russia Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 40. Asia-Pacific Oncolytic Virus Manufacturing Services Revenue YoY (2020-2031) & (US$ Million)
 Figure 41. Asia-Pacific Top 8 Players Oncolytic Virus Manufacturing Services Revenue (US$ Million) in 2024
 Figure 42. Asia-Pacific Oncolytic Virus Manufacturing Services Revenue (US$ Million) by Type (2020-2031)
 Figure 43. Asia-Pacific Oncolytic Virus Manufacturing Services Revenue (US$ Million) by Application (2020-2031)
 Figure 44. Indonesia Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 45. Japan Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 46. South Korea Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 47. Australia Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 48. India Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 49. Indonesia Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 50. Vietnam Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 51. Malaysia Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 52. Philippines Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 53. Singapore Oncolytic Virus Manufacturing Services Revenue (2020-2031) & (US$ Million)
 Figure 54. Central and South America Oncolytic Virus Manufacturing Services Revenue YoY (2020-2031) & (US$ Million)
 Figure 55. Central and South America Top 5 Players Oncolytic Virus Manufacturing Services Revenue (US$ Million) in 2024
 Figure 56. Central and South America Oncolytic Virus Manufacturing Services Revenue (US$ Million) by Type (2020-2031)
 Figure 57. Central and South America Oncolytic Virus Manufacturing Services Revenue (US$ Million) by Application (2020-2031)
 Figure 58. Brazil Oncolytic Virus Manufacturing Services Revenue (2020-2025) & (US$ Million)
 Figure 59. Argentina Oncolytic Virus Manufacturing Services Revenue (2020-2025) & (US$ Million)
 Figure 60. Middle East and Africa Oncolytic Virus Manufacturing Services Revenue YoY (2020-2031) & (US$ Million)
 Figure 61. Middle East and Africa Top 5 Players Oncolytic Virus Manufacturing Services Revenue (US$ Million) in 2024
 Figure 62. South America Oncolytic Virus Manufacturing Services Revenue (US$ Million) by Type (2020-2031)
 Figure 63. Middle East and Africa Oncolytic Virus Manufacturing Services Revenue (US$ Million) by Application (2020-2031)
 Figure 64. GCC Countries Oncolytic Virus Manufacturing Services Revenue (2020-2025) & (US$ Million)
 Figure 65. Israel Oncolytic Virus Manufacturing Services Revenue (2020-2025) & (US$ Million)
 Figure 66. Egypt Oncolytic Virus Manufacturing Services Revenue (2020-2025) & (US$ Million)
 Figure 67. South Africa Oncolytic Virus Manufacturing Services Revenue (2020-2025) & (US$ Million)
 Figure 68. Oncolytic Virus Manufacturing Services Industry Chain Mapping
 Figure 69. Channels of Distribution (Direct Vs Distribution)
 Figure 70. Bottom-up and Top-down Approaches for This Report
 Figure 71. Data Triangulation
 Figure 72. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

Global Oncolytic Virus Manufacturing and Development Services Market Research Report 2024
Global Oncolytic Virus Market Insights Forecast to 2030
Global Oncolytic Virus Therapy Market Research Report 2025
Global Oncolytic Virus Cancer Immunotherapy Market Insights Forecast to 2030
Global Viral Vector Development and Manufacturing Services Market Research Report 2025
Global Viral Vector Manufacturing for Gene Therapy Market Research Report 2024
Global Oncolytic Viral Drugs Market Research Report 2024
Global Viral Vector Manufacturing CDMO Services Market Research Report 2024
Global Nanomedicine Development and Manufacturing Services Market Research Report 2025
Global Cell Therapy Biomanufacturing Market Research Report 2024
Global Stem Cell Biomanufacturing Market Research Report 2024
Global GMP Viral Vector Manufacturing Market Research Report 2024
Global Oncolytic Virus Immunotherapy Market Research Report 2024
Global Cell and Gene Therapy CDMO Services Market Research Report 2024
Global Research Grade Viral Vector Packaging Service Market Research Report 2025
Global Exosome Manufacturing Service Market Research Report 2024
Global mRNA Development and Manufacturing Services Market Research Report 2025
Global Immuno Oncology Service Market Research Report 2024
Global Clinical Trial Manufacturing Service Market Research Report 2025
Viral Vector Packaging Services Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Pharmacy Chatbot Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10T20319
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Inline Pharmaceutical Packaging Leak Detection System Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-6Q20319
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Radiological Marker Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35Z19949
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Pharmaceutical Biomanufacturing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-26E19785
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions